Artelo Biosciences, Inc. (NASDAQ:ARTL) Receives Consensus Recommendation of “Buy” from Analysts

Artelo Biosciences, Inc. (NASDAQ:ARTL) has received an average recommendation of “Buy” from the five research firms that are presently covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a hold rating, one has given a buy rating and two have given a strong buy rating to the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $24.00.

Several brokerages have recently weighed in on ARTL. D. Boral Capital reiterated a “hold” rating on shares of Artelo Biosciences in a research report on Monday, September 8th. Wall Street Zen lowered shares of Artelo Biosciences to a “strong sell” rating in a research report on Saturday, August 9th. Finally, D Boral Capital lowered shares of Artelo Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Monday, September 8th.

Artelo Biosciences Stock Performance

Shares of Artelo Biosciences stock opened at $5.51 on Friday. The firm’s 50-day simple moving average is $8.73 and its 200-day simple moving average is $7.98. Artelo Biosciences has a twelve month low of $4.20 and a twelve month high of $28.60. The firm has a market cap of $3.86 million, a P/E ratio of -0.29 and a beta of 1.46.

Artelo Biosciences (NASDAQ:ARTL) last issued its earnings results on Wednesday, August 13th. The company reported ($5.61) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($5.48). On average, equities analysts forecast that Artelo Biosciences will post -2.62 earnings per share for the current fiscal year.

Artelo Biosciences Company Profile

Artelo Biosciences, Inc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders.